Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E75.44 EPS (ttm)0.94 Insider Own0.10% Shs Outstand1.69B Perf Week-0.08%
Market Cap119.64B Forward P/E21.94 EPS next Y3.22 Insider Trans-19.91% Shs Float1.67B Perf Month-0.11%
Income1.57B PEG3.30 EPS next Q0.66 Inst Own74.40% Short Float0.99% Perf Quarter13.16%
Sales16.91B P/S7.07 EPS this Y-22.30% Inst Trans-0.03% Short Ratio2.84 Perf Half Y3.52%
Book/sh8.62 P/B8.19 EPS next Y25.06% ROA4.90% Target Price76.38 Perf Year8.13%
Cash/sh2.54 P/C27.78 EPS next 5Y22.85% ROE10.70% 52W Range50.91 - 75.12 Perf YTD3.26%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-6.00% Beta0.51
Dividend %2.15% Quick Ratio1.30 Sales past 5Y-3.20% Gross Margin76.00% 52W Low38.69% ATR1.30
Employees25000 Current Ratio1.50 Sales Q/Q8.70% Oper. Margin11.60% RSI (14)43.69 Volatility1.76% 1.59%
OptionableYes Debt/Eq0.47 EPS Q/Q0.50% Profit Margin9.30% Rel Volume1.28 Prev Close72.64
ShortableYes LT Debt/Eq0.46 EarningsJul 28 BMO Payout159.00% Avg Volume5.79M Price70.61
Recom2.30 SMA20-2.33% SMA50-1.02% SMA2007.63% Volume7,395,857 Change-2.79%
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-24-16 06:07PM  Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
04:39PM  Brexit may make health care stocks a good defensive play at MarketWatch
04:10PM  Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola Business Wire
09:42AM  Why Investors Are Paying a Premium for These 3 Drugmakers at Motley Fool
Jun-22-16 07:01PM  Cramer: Let's Put Brexit in Its Historic Context
04:55PM  SolarCity and Bristol-Myers climb, Adobe and HP stumble
02:05PM  Whats so groundbreaking about Curis new cancer drug that just began human trials? at
10:53AM  GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
08:36AM  Immuno-Oncology: The Strategic Supernova In Cancer Today at Forbes
Jun-21-16 04:21PM  3 Ways This $30 Billion Market Is Bristol's for the Taking at Motley Fool
11:22AM  Bristol-Myers Squibb Co. Value Analysis (NYSE:BMY) : June 21, 2016
Jun-20-16 04:20PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
04:15PM  Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer Business Wire
03:05PM  Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
08:19AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : June 20, 2016
08:00AM  Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
04:46AM  Calls For Actions Grow Louder
Jun-17-16 09:45AM  Will Merck Keytruda Surpass Bristol-Myers Opdivo In Immunotherapies Race?
09:09AM  Cheniere Energy Inc. (LNG) and Vince Holding Corp (VNCE) See Their CEOs Buy Shares; Three Other Companies Register Insider Selling at Insider Monkey
12:19AM  Allergan Glaucoma Gel Stent Filing Accepted for FDA Review
Jun-16-16 07:46PM  Don't Make it Complicated, Own Drug Stocks
07:00PM  Merck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer Battle at Motley Fool
04:39PM  Mercks Keytruda Extends Lung Cancer Survival As Sole Therapy
10:10AM  Stock Market News for June 16, 2016
09:11AM  Combat Volatility with These 5 Low Beta Stocks
Jun-15-16 08:29PM  Jim Cramer's 'Mad Money' Recap: Sit on the Sidelines for Now, Then Pounce
03:24PM  This Fund Wants to Make It Easier to Invest in Biotech Stocks at Fortune
09:45AM  Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
09:30AM  Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
08:50AM  Will Bristol-Myers Squibb (BMY) Crush Estimates at Its Next Earnings Report?
06:57AM  PeptiDream Achieves Milestone for Initiation of Clinical Development for Bristol-Myers Squibbs First Collaboration Product Candidate Business Wire
Jun-14-16 04:44PM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
01:37PM  Don't Make It Complicated, Own Drug Stocks
11:59AM  Immunotherapy: A Teacher's Journey to Health at MarketWatch
11:28AM  Revance's Lead Candidate Fails in Phase III Crow's Feet Study
08:30AM  Superbug Hearing: Will Congress Pick Up Ali's Fight Against Sepsis? at Forbes
Jun-13-16 04:08PM  5 Things Organovo Holdings, Inc. Management Wants You to Know at Motley Fool
04:01PM  [$$] Alpine Immune Sciences Closes $48M Series A for Cancer Immunotherapy at The Wall Street Journal
09:56AM  Agios Reports Favorable Phase II PK Deficiency Study Data
08:50AM  Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
03:16AM  ECB Bond Buying Destabilizes All Financial Markets
Jun-10-16 10:36AM  Cramer: To Stabilize, the Market Needs Stable Oil
10:19AM  [$$] Bristol-Myers, a Top Pharmaceuticals Pick at
08:53AM  Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
08:05AM  Major Pharma Has Short Sellers on the Run at 24/7 Wall St.
08:04AM  3 Cutting-Edge Healthcare Stocks Millennials Should Seriously Consider Buying at Motley Fool
07:00AM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
02:30AM  New Data on Bristol-Myers Squibbs Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial Business Wire
Jun-09-16 02:32PM  These Are the Most Promising Experimental Cancer Drugs at Fortune
10:00AM  Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28 Business Wire
09:07AM  What Caused Alexion Pharmaceuticals Fall?
06:59AM  Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Association Business Wire
Jun-08-16 03:45PM  Exelixis, Inc. Setting New Standard of Care at Motley Fool
12:30PM  These Two Healthcare Companies Just Augmented Their Dividends
10:09AM  Bristol-Myers Squibb Reveals Fresh Rheumatoid Arthritis Research And Real-World Data At European Congress Of Rheumatology
07:48AM  Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016) Business Wire
07:34AM  Pfizer's Xeljanz Positive in Active Psoriatic Arthritis Study
Jun-07-16 04:15PM  Bristol-Myers Squibb Announces Dividend Business Wire
10:22AM  Bristol-Myers Squibb seen holding gains
07:47AM  Bristol-Myers And MD Anderson Cancer Center Makes Fresh Research Alliance In Immuno-Oncology Focused On Lung-Cancer
06:59AM  Bristol-Myers Squibb and MD Anderson Announce New Research Collaboration in Immuno-Oncology Focused on Lung Cancer Business Wire
Jun-06-16 05:37PM  AbbVie Breakout Failing As Cancer Drug Data From $5.8 Billion Buy Disappoint
05:04PM  Bristol-Myers Hits 17-Year High Showing Off Cancer Portfolio
01:40PM  How Credit Suisse Views Major Pharma After ASCO at 24/7 Wall St.
12:17PM  Best bets in health care
10:52AM  Pfizer (PFE) Presents Data on Utomilumab for Solid Tumors
10:36AM  Winners And Losers From Cancer's Big Event at Forbes
08:42AM  What AbbVie Bought for $5.8 Billion at Motley Fool
06:59AM  Long-Term Data from Two Trials Evaluating the Opdivo® (nivolumab) and Yervoy® (ipilimumab) Regimen in Advanced Melanoma Continues to Validate Bristol-Myers Squibbs Immuno-Oncology Combination Approach Business Wire
05:00AM  Neither a Trend Nor an Inflection Point
Jun-05-16 12:42PM  5 Trade Ideas for Monday: Agrium, Biogen, Bristol-Myers, Bloomin' Brands and Canadian National Railway
11:24AM  Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting Business Wire
09:00AM  First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic Colorectal Cancer Business Wire
08:06AM  Promising Response Rates with Opdivo® (nivolumab) Observed in Advanced Form of Bladder Cancer from Phase 1/2 Study CheckMate -032 Business Wire
Jun-04-16 02:27PM  Opdivo® (nivolumab) and Yervoy® (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase 1b Study CheckMate -012 Business Wire
02:27PM  Bristol-Myerss Drug Combination Boosts Lung Cancer Benefit at Bloomberg
Jun-03-16 12:25PM  On tap at ASCO
10:10AM  Stock Market News for June 03, 2016
09:52AM  J&J to Buy Vogue for ~$3.3B, Boost Hair Care Portfolio
09:40AM  Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Jun-02-16 02:34PM  What You Need to Know About the Worlds Biggest Cancer Conference at Fortune
03:04AM  Changes in Sanofis Profitability in 1Q16
Jun-01-16 12:58PM  Whats AstraZenecas Largest Revenue Contributor?
May-31-16 03:04PM  These 2 Billionaires Are Dumping Exelixis' Stock. Should You? at Motley Fool
11:06AM  Why Bristol-Myers Squibbs Profitability Has Shifted
10:30AM  Bristol-Myers Squibb to Take Part in Goldman Sachs 37th Annual Global Health Care Conference Business Wire
10:04AM  [$$] The Roundup at The Wall Street Journal
09:06AM  Understanding Bristol-Myers Squibbs Other Segments
09:03AM  AstraZeneca Reports Positive Phase III Data on Faslodex
05:33AM  Pushing Against the Status Quo
May-30-16 09:22AM  Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod
09:06AM  Why Opdivo Matters: Inside Bristol-Myers Squibbs Oncology Drug
07:30AM  Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
May-29-16 10:15AM  Key Movers to Look for Ahead of ASCO at 24/7 Wall St.
May-28-16 02:18PM  Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pipeline at Motley Fool
09:40AM  Portola Pharmaceuticals: Does New Data Get It Back on Track? at Motley Fool
08:30AM  3 Stories To Watch At The Years Biggest Cancer Conference
May-27-16 03:31PM  This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales at Motley Fool
11:07AM  Inside Bristol-Myers Squibbs Virology Segment
09:07AM  Inside Bristol-Myers Squibbs Oncology Segment
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM
ANDREOTTI LAMBERTODirectorOct 06Sale59.7311,600692,904524,252Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorOct 05Sale61.9911,600719,027535,852Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorSep 03Sale59.5711,600691,032546,874Sep 03 06:34 PM
ANDREOTTI LAMBERTODirectorSep 02Sale59.2211,600687,005558,474Sep 03 06:34 PM
Blin EmmanuelSVP, Head of CommercializationJul 02Option Exercise0.009510953Jul 07 05:13 PM
Gordon MurdoSVP, Head of Worldwide MarketsJul 01Option Exercise0.002,33502,540Jul 06 07:17 PM